NanoViricides rises on COVID-19 drug licensing deal

NanoViricides,

14/09/2021 12:33

** Antiviral drug developer's shares  NNVC.A  rise 10.5% to
$4.50 premarket
    ** Co enters into licensing agreement with TheraCour Pharma
Inc for antiviral drugs to treat SARS-CoV-2 and its variants
 urn:newsml:reuters.com:*:nPn30fslKa
    ** NNVC obtains worldwide, exclusive license to use, sell
and distribute antiviral drugs that treat human coronavirus
infections using TheraCour's technology and intellectual
property
    ** NanoViricides will not make any upfront cash payments to
TheraCour and has agreed to certain milestone payments
    ** NNVC says it is currently working on taking its two
COVID-19 lead drug candidates, NV-CoV-2- and NV-CoV-2-R, into
human clinical trials
    ** Up to Monday's close, stock had risen ~41.8% this year


 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))